Inhibition of Thrombin by Peptides Containing Lysyl-α-Keto Carbonyl Derivatives

Summary

Several H-N-Me-D-Phe-Pro-Lysyl-α-keto carbonyl derivatives were shown to be potent thrombin inhibitors (K_i 0.2 to 27 nM). The inhibitory potencies of these compounds toward tissue plasminogen activator, plasmin and factor Xa were minimal; however, substantial cross-reactivity versus trypsin was observed (K_i values from 0.5 to 1500 nM). Inhibition of thrombin by α-keto carbonyl compounds appeared to occur via a one-step reversible reaction. The α-keto carbonyl inhibitors bound thrombin with a second order rate constant (k, 1–4 μM^-1s^-1) that was 10–100-fold slower than that expected for a diffusion-controlled reaction. Certain α-kelo earbonyl inhibitors were as potent (on a weight basis) as hirudin when evaluated in a rat arterial thrombosis model. The modest oral bioavailability (10–19%) in rats demonstrated for three of the α-keto carbonyl thrombin inhibitors suggests the possibility that α-keto amide containing thrombin inhibitors may have utility as orally-active antithrombotic agents.

• References

• 1 Mehdi S. Synthetic and naturally occurring protease inhibitors containing an electrophilic carbonyl group. Bioorganic Chem 1993; 21: 249-259
• 2 Hu LY, Abeles RH. Inhibition of cathepsin B and papain by peptidyl α-keto esters, α-keto amides, α-diketones and α-keto acids. Arch Biochem Biophys 1990; 281: 271-274
• 3 Ocain TD, Rich DH. α-keto amide inhibitors of aminopeptidases. J Med Chem 1992; 35: 451-456
• 4 Fusetani N, Matsunaga S, Matsumoto H, Takebayashi Y. Cyclotheonamides, potent thrombin inhibitors, from a marine sponge Theonella sp. J Am Chem Soc 1990; 112: 7053-7051
• 5 Hagihara M, Schreiber SL. Reassignment of stereochemistry and total synthesis of the thrombin inhibitor Cyclotheonamide B. J Am Chem Soc 1992; 114: 6570-6571
• 6 Wipf P, Kim H. Total synthesis of Cyclotheonamide A. J Org Chem 1993; 58: 5592-5594
• 7 Lewis SD, Ng AS, Baldwin JJ, Fusetani N, Naylor AM, Shafer JA. Inhibition of thrombin and other trypsin-like serine proteinases by Cyclotheonamide A. Thromb Res 1993; 70: 173-190
• 8 Maryanoff BE, Qiu X, Padmanabhan KP, Tulinsky A, Almond Jr HR, Andrade-Gordon P, Greco MN, Kauffman JA, Nicolaou KC, Liu A, Brungs PH, Fusetani N. Molecular basis for the inhibition of human a-thrombin by the macrocyclic peptide cyclotheonamide A. Proc Natl Acad Sci USA 1993; 90: 8048-8052
• 9 Lee AY, Hagihara M, Karmacharya R, Albers MW, Schreiber SL, Clardy J. Atomic structure of the trypsin-Cyclotheonamide A complex: Lessons for the design of serine protease inhibitors. J Am Chem Soc 1993; 115: 12619-12620
• 10 Tanizawa K, Kanaoka Y, Wos JD, Lawson WB. Transition-state inhibition of thrombin and trypsin by amidinophenylpyruvates. Biol Chem Hoppe-Seyler 1985; 366: 871-878
• 11 Hijikata A, Okamoto S, Kikumoto R, Tamao Y. Kinetic studies on the selectivity of a synthetic thrombin-inhibitor using synthetic peptide substrates. Thromb Haemost 1979; 42: 1039-1045
• 12 Walter J, Bode W. The x-ray crystal structure analysis of the refined complex formed by bovine trypsin and p-amidinophenylpyruvate at 1.4 Å resolution. Hoppe-Seyler’s Z Physiol Chem 1983; 364: 949-959
• 13 Chen Z, Li Y, Mulichak AM, Lewis SD, Shafer JA. Crystal structure of human α-thrombin complexed with hirugen and APPA (p-Amidinophenylpyruvate) at 1.6 Å resolution. Proteins (Submitted for Publication)
• 14 Iwanowicz EJ, Lin J, Roberts DG M, Michel IM, Seiler SM. α-Hydroxy- and α-ketoester functionalized thrombin inhibitors. Bio Med Chem Lett 1992; 2: 1607-1612
• 15 Brady SF, Sisko JT, Stauffer KJ, Colton CD, Qiu H, Lewis SD, Ng AS, Shafer JA, Bogusky MJ, Veber DF, Nutt RF. Amide and α-keto carbonyl inhibitors of thrombin based on arginine and lysine: Synthesis, stability, and biological characterization. Bioorganic and Med. Chem. (In Press)
• 16 Lehman ED, Joyce JG, Bailey FJ, Markus HZ, Schultz LD, Dunwiddie CT, Jacobson MA, Miller WJ. Expression, purification and characterization of multigram amounts of a recombinant hybrid HV1-HV2 hirudin variant expressed in Saccharomyces cerevisiae. Prot Exp and Pur 1993; 4: 247-255
• 17 Morrison JF, Walsh CT. The behavior and significance of slow-binding enzyme inhibitors. Adv Enzymol 1988; 61: 201-300
• 18 Morrison JF, Stone SR. Approaches to the study and analysis of the inhibition of enzymes by slow-and tight-binding inhibitors. Mol Cell Biophy 1985; 2: 347-368
• 19 Evans SA, Olson ST, Shore JD. p-Aminobenzamidine as a fluorescent probe for the active site of serine proteinases. J Biol Chem 1982; 257: 3014-3017
• 20 Olson ST, Shore JD. Demonstration of a two-step reaction mechanism for inhibition of a-thrombin by antithrombotic III and identification of the step affected by heparin. J Biol Chem 1982; 257: 14891-14895
• 21 Kurz KD, Main BW, Sandusky GE. Rat model of arterial thrombosis induced by ferric chloride. Thromb Res 1990; 60: 269-280
• 22 Bajusz S, Szell E, Bagdy D, Barabas E, Horvath G, Dioszegi M, Fittler Z, Szabo G, Jahasz A, Tomori E, Szilagyi G. Highly active and selective anticoagulants, D-Phe-Pro-Arg-H, a free tripeptide aldehyde prone to spontanious inactivation, and its stable N-methyl derivation, D-Me-Phe-Pro-Arg-H. J Med Chem 1990; 33: 1729-1735
• 23 Claeson G. Synthetic peptides and peptidomimetics as substrates and inhibitors of thrombin and other proteases in the blood coagulation system. Blood Coagul and Fibrin 1994; 5: 411-436
• 24 Kaiser B, Hauptmann J. Pharmacology of Synthetic Thrombin inhibitors of the tripeptide type. Cardio Drugs Reviews 1992; 1: 71-87 25
• 25 Kaiser B, Hauptmann J, Markwardt F. Studies of the pharmacodynamics of synthetic thrombin inhibitors of the basically substituted N-α-acryl sulfonylated phenylalanine amide type. Die Parm 1987; 42: 119-121
• 26 Hauptmann J. Pharmacology of benzamidine-type thrombin inhibitors. Folia Haematol, Leipzig 1982; 109: 89-97
• 27 Mattson C, Eriksson E, Nilsson S. Anti-coagulant and anti-thrombotic effects of some protease inhibitors. Folia Haematol, Leipzig 1982; 109: 43-51
• 28 Ostrowski LE, Ahsan A, Suthar BP, Pagast P, Bain DL, Wong C, Patel A, Schultz RM. Selective inhibition of proteolytic enzymes in an in vivo mouse model for experimental metastasis. Cancer Research 1986; 46: 4121-4128
• 29 Kettner C, Mersinger L, Knabb R. The selective inhibition of thrombin by peptides of boroarginine. J Biol Chem 1990; 265: 18289-18297
• 30 Markwardt F, Nowak G, Hoffmann J. Comparative studies on thrombin inhibitors in experimental microthrombosis. Thromb Haemost 1983; 49: 235-237